Private equity firm buys Tanzania’s generic drug maker Zenufa for undisclosed price

Catalyst Principal Partners, a private equity firm focused on East Africa, has picked up Zenufa Laboratories, Tanzania’s second-largest generic drug maker.

Terms of the deal weren’t disclosed.

Zenufa manufactures a wide range of over-the-counter and prescription medicines for the Tanzanian market, and was the first facility in the country to be  certified as 100% cGMP compliant.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“While the healthcare sector remains dominated by foreign imports representing majority of Tanzania’s medicine supply, as an established local pharmaceutical manufacturer, Zenufa is uniquely positioned to meet the rising healthcare needs of the population through offering affordable, quality medication manufactured to the highest international best practice standards,” Martha Osier, a Catalyst investment manager, said in a statement.

The Zenufa purchase represents Catalyst’s fourth investment in Tanzania and its second in the healthcare sector. It bought Mimosa Pharmacy in 2014, which now operates under the name “Goodlife Pharmacy” and is rapidly expanding its pharmacy retail business.

- here’s the release

Related Article:
Tanzania, like GlaxoSmithKline, learns delivery tricks from Coke

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.